Why the Proteomics (ASX:PIQ) share price is flying 5%

The Proteomics (ASX: PIQ) share price was off to a good start today before falling flat on news it has achieved ISO certification.

| More on:
asx share price fall represented by lady in striped tshirt making sad face against orange background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After flying 5% higher this morning, it was downhill all the way for the Proteomics International Laboratories Ltd (ASX: PIQ) share price today.

At the market close today, shares in the medical technology company were right back where they started, trading at $1.18. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.02% higher.

Today's price movement comes as the company announced one of its products received ISO certification.

ISO Certification

In today's release, Proteomics International advised it has received ISO 13485 certification. ISO certification is an independent process that gives assurance a product or service "meets specific requirements".

The company said achieving certification would aid it in commercial discussions going forward with global diagnostic companies. It also believes the certification will "widen" the market for its PromarkerD test and make it easier to achieve regulatory approval around the world.

The PromarkerD test is used for the early detection of chronic kidney disease (CKD) in patients with type-2 diabetes. According to Proteomics, clinical studies showed 86% of patients with type-2 diabetes went on to develop CKD within 4 years.

PromarkerD tests are manufactured in Australia under licence. The company is anticipating demand for the product to boom worldwide. Recognising this, Proteomics says it is in discussions with several manufacturers in the northern hemisphere "with the objective of streamlining the future production". 

Proteomics managing director Dr Richard Lipscombe welcomed the progress, saying:

The ISO 13485 manufacturing standard provides the foundation to regulatory requirements for medical diagnostics and has been adopted by markets including the European Union, Australia, Japan, Canada and, most recently, the United States.

Proteomics share price snapshot

The Proteomics share price has increased 280% over the past 12 months and is up 51% year-to-date. At the same time, it has fallen 13% since achieving its all-time high on Monday.

Proteomics International has a market capitalisation of $129.7 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a business person checks his mobile phone outside a Wall Street office with an American flag and other business people in the background.
Healthcare Shares

Guess which ASX 200 stock is rocketing on big US news

Let's see what is getting investors excited today.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

3 reasons CSL shares could rocket 40% into 2026

Two leading experts forecast a big rebound for CSL shares. But why?

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Healthcare Shares

Why did CSL shares crash 21% in August?

This biotech has a month to forget in August.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX health insurance shares: Does Macquarie still prefer NIB over Medibank Private shares?

This expert has a clear favourite here.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Macquarie tips 12% return for this ASX 200 healthcare stock

Healthy returns could be on the cards for buyers of this share.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Healthcare Shares

Down 32%! Does Macquarie rate this ASX 200 stock as a buy?

The broker has given its verdict on this blue chip.

Read more »

Arrows pointing upwards with a man pointing his finger at one.
Healthcare Shares

Why Mesoblast shares could rocket 60% higher

Let's see why Bell Potter is tipping this stock as a buy right now.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Healthcare Shares

Down 53%! Bell Potter says this beaten down ASX 200 stock is a buy

The broker sees recent weakness as a buying opportunity for investors.

Read more »